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Abstract: Biomaterial-related infections are a persistent burden on patient health, recovery, 
mortality and healthcare budgets. Self-assembled antimicrobial peptides have evolved from 
the area of antimicrobial peptides. Peptides serve as important weapons in nature, and 
increasingly medicine, for combating microbial infection and biofilms. Self-assembled 
peptides harness a “bottom-up” approach, whereby the primary peptide sequence may be 
modified with natural and unnatural amino acids to produce an inherently antimicrobial 
hydrogel. Gelation may be tailored to occur in the presence of physiological and infective 
indicators (e.g. pH, enzymes) and therefore allow local, targeted antimicrobial therapy at the 
site of infection. Peptides demonstrate inherent biocompatibility, antimicrobial activity, 
biodegradability and numerous functional groups. They are therefore prime candidates for the 
production of polymeric molecules that have the potential to be conjugated to biomaterials 
with precision. Non-native chemistries and functional groups are easily incorporated into the 
peptide backbone allowing peptide hydrogels to be tailored to specific functional 
requirements. This article reviews an area of increasing interest, namely self-assembled 
peptides and their potential therapeutic applications as innovative hydrogels and biomaterials 
in the prevention of biofilm-related infection. 
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1. Introduction 
Biomaterials have an increasingly important role in patient care. Approximately five million medical 
devices and implants are used in the US each year [1]. They are beneficial not only as temporary 
interventions but also as permanent features to replace or facilitate normal bodily functions. There is a 
diverse array of such materials available including: intravascular and urinary catheters, heart valve 
prostheses, artificial hip joints, dental implants, and intraocular lenses [2]. Their use is particularly 
prominent in modern medicine as population demographics demonstrate an increasing trend toward an 
ageing population, in tandem with increased life expectancy and improved healthcare [3]. 
Grainger and colleagues researched the contribution medical devices have to improving patients’ 
quality of life [4]. They concluded that 50% of patients with aortic heart valve disease could potentially 
die within three years of diagnosis. Valve replacements resulted in an increase in ten year survival to 
approximately 70% of patients. Despite this improvement, 60% of these patients were shown to have 
device-associated complications thus affecting patient quality of life. Implantation of a medical device 
is an invasive surgical procedure that may result in irritation, wounding and infection of the surgical site. 
A macrophage-mediated collection of immune responses, collectively referred to as the host or foreign 
body response, is triggered leading to compromised device function and scarring of surrounding tissue [5]. 
Anderson and colleagues provide a comprehensive outline of the sequence of events following surgical 
implantation [6]. The initial response follows the normal wound-healing cascade of: injury, blood-
material interactions, provisional matrix formation, acute inflammation, chronic inflammation, 
granulation tissue development, foreign body reaction, and fibrosis. The resulting host or foreign body 
response to a device is estimated to affect approximately 5% of patients and can have a significant impact 
on patient recovery and long-term health. Surgical trauma can result in a compromised immune response 
leading to unchallenged accumulation and adherence of pathogens at the site of implantation, resulting 
in biofilm formation. Biomaterials provide an optimal surface for biofilm formation [1,7]. The long-term 
effects are considerable. Economically, biomaterial associated infections have costly implications on 
health-care budgets. Bacterial accumulation and the subsequent formation of a biofilm contributes to an 
infectious profile 10–1000 times more resistant to standard therapeutic regimens, leading to 
compromised implant function and/or failure [8]. Symptomatic infection often occurs within 2 weeks of 
implantation [4,6,7,9]. 
Biofilms are phenotypically heterogeneous, sessile microbial communities that form at biotic and 
abiotic sites. They may be composed of a single or multiple species (poly-microbial) of bacteria and 
fungi [10–12]. Biofilm formation can be divided into three significant stages: (1) initial non-specific, 
reversible primary adhesion; (2) specific irreversible adhesion (coating of the device, transport of cells 
to the interface, adhesion of cells; accumulation at the surface involving biomolecular processes 
including quorum sensing, up-regulation of virulence factors and secretion of extracellular polymers; (3) 
biofilm detachment/dispersal and recolonization of alternative sites. Following implantation the surface 
chemistry of a biomaterial is modified by the laying down of a host-derived conditioning film. Primary 
adhesion is dependent on two key factors—hydrophilicity and charge at the cell-device interface. 
Primary adhesion is a non-specific process mediated by hydrophobic and van der Waal’s interactions 
between the microbial cell and the generally hydrophobic surface, as is the case for silicone [1,10,11]. 
Binding sites such as fibrinogen, fibronectin, vitronectin, binding autolysin, albumin and extracellular 
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matrix binding protein become exposed on the biomaterial surface. Microbial adhesins, for example 
teichoic acid expressed in Staphylococcus epidermidis, specifically recognize binding sites and mediate 
adherence to the surface via covalent attachment. 
The potential for microbial spoilage is not confined to hydrophobic surfaces. More hydrophilic 
materials, for example Teflon®, also suffer from microbial contamination due to mechanical rather than 
chemical factors [13]. MacKintosh and co-workers investigated how the modification of poly(ethylene 
terephthalate) surface chemistry affected bacterial-biomaterial interaction, attachment and subsequent 
biofilm formation of Staphylococcus epidermidis [14]. They demonstrated that hydrophobic interactions 
do influence the adhesion of bacteria to the material surface. Of greater significance is the presence of 
serum proteins within the conditioning film. These tend to have a greater effect on adhesion and biofilm 
formation in vivo. Similar research performed by the Gottenbos group suggested that biofilm formation 
is a complex relationship involving not only the biomaterial surface properties and the ability of the 
bacteria to bind to a given surface, but also the availability of nutrients at the site of adherence [15]. 
Accumulation on a surface occurs when bacterial cells multiply and form multi-layered cell clusters 
resulting in a complex three dimensional architecture- the classic biofilm [16]. The biofilm is maintained 
through specific quorum sensing pathways. Quorum sensing is a communicatory and regulatory process 
controlling the up- and down-regulation of genes that govern virulence and adhesion factors, relative to 
environmental conditions and population density. It is an essential process for biofilm survival ensuring 
that biofilms act as a mutualistic community rather than individual cells [17]. As the microbial 
population increases the supply of nutrients and oxygen become limited within the confines of the 
biofilm. Therefore biofilm bacteria generally grow more slowly than planktonic bacteria due to a reduced 
rate of respiration/metabolism. The protective environment, provided by the polymeric exopolysaccharide 
matrix, means that bacteria are much more resistant to the host’s immune response and therapeutic 
antimicrobials than their planktonic counterparts [1,18,19]. Biofilm mediated infections are thus extremely 
difficult to treat and the extent and rate of eradication is largely determined by the most resistant 
phenotype within the biofilm. Chemotherapeutic failure often results in surgical removal of the 
biomaterial, particularly those involving Staphylococcus aureus and Candida species [7]. Removal, 
combined with potential chemotherapeutic failure, is not an ideal scenario as concerns grow regarding 
increased antimicrobial resistance, and the relative lack of new antimicrobials in development [20–22]. 
Typical biofilm related medical device infections include: Catheter associated urinary tract infections; 
peristomal skin infections following insertion of percutaneous endoscopic gastrostomy feeding tubes; 
and pneumonia or tracheobronchitis with tracheostomy devices. The most commonly implicated 
pathogens are: staphylococci, enterococci, Escherichia coli, Proteus mirabilis, Pseudomonas, and 
Candida [19,23,24]. The prognosis for such infections depend on the patient’s initial health, which in 
many cases is poor due to age and co-morbidities, and the duration of implantation. Medical implants 
are commonly required in immunocompromised patients. Therefore, insertion of an implant and the 
resulting trauma further compromises the immune response increasing patient recovery time and morbidity. 
Numerous strategies to reduce biomaterial-associated infections have been developed but few have 
translated to clinical practice [9]. Hospital stays can be up to two and a half times longer than for 
uninfected patients, with a total of 3.6 million extra days being spent in hospital per year in England. 
Nosocomial infections cost the health sector in England almost £1 billion per year [25]. In the United 
States medical device related infections contribute to over 50,000 deaths per year [4]. As for the majority 
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of disease states prevention is the key aim. Poor hygiene practice within the healthcare setting has been 
shown to increase the risk of infection. Simple measures such as correct hand washing technique, by 
both staff and patients, can have a dramatic decrease in infections [26]. There is an increasing demand 
globally for medical devices to replace normal physiological function. Therefore managing and 
preventing implant associated infections is a huge challenge [1]. These problems have to be addressed 
on a global-scale and require the development of biomaterials that are both biocompatible and anti-
infective. This review examines the current strategies employed to reduce the occurrence of biofilm 
mediated device related infections and investigates the potential of future innovative strategies, namely 
peptide based biomaterials. 
2. Current Research Based Strategies for the Prevention of Medical Device Related Infection 
Biomaterials cover a diverse range of pharmaceutical applications from drug delivery to tissue 
engineering [27]. Every device is prone to infection. Surfaces are particularly vulnerable to biofilm 
formation. Therefore antimicrobial coatings are a plausible solution for the development of devices with 
anti-infective properties. Implantation of medical devices may be classified as temporary or 
permanent/long-term. Temporary devices, for example contact lenses, are not fully integrated into the 
host tissue. Other internally-based devices, for example heart valves, tend to be more permanent. 
Prevention of temporary device-related infections can be managed with non-adhesive, antimicrobial 
impregnated or releasing coatings, which kill bacteria that come into contact with the device [9]. 
Permanent device coatings must be multi-functioning, facilitating incorporation of the device into the 
host tissue whilst simultaneously preventing microbial adhesion over an extended period within the 
lifetime of the device. Examples of such coatings include those investigated by the Saldarriaga  
group [28]. They produced multi-component cross-linked poly(ethylene-glycol) based polymers and 
demonstrated that the degree of hydration and steric hindrance contributed to the efficacy of these multi-
functioning coatings. Hydrogel coatings display great promise as they can incorporate and/or release 
antimicrobial agents. They allow for improved tissue integration and a reduction in biofilm formation [29]. 
Hydrogels comprise a group of insoluble, swellable, hydrophilic polymers. When fully swollen they are 
composed of a significant amount of water (up to ~99%) but also display solid-like properties which 
provide desirable characteristics such as increased mechanical strength. Hydrogel classification is 
dependent upon the nature of the crosslinks which bind the hydrogel structure, influencing its swelling 
ability. Chemical hydrogels are also influenced by the structure of the primary monomer chains and the 
density of the crosslinks within the polymer system. Hydrogel architecture is also determined by 
secondary non-covalent molecular interactions and entangled molecules. The presence of a porous three-
dimensional network means hydrogels are ideal biomaterials as they structurally similar to the 
extracellular matrix and tissue. The presence of defined functional groups, for example carboxylic acids, 
allow for the production of bioactive biomaterials that respond to environmental, chemical and physical 
stimuli. These so-called ‘smart’ polymer systems display significant potential as future drug delivery 
and biomaterial platforms [30–32]. 
Current research has seen an increased focus on the antimicrobial properties of silver. Hydrogel/silver 
coated urinary catheters have been investigated and promising results obtained. A reduction in the 
primary bacterial adherence was observed in comparison to a standard silicone catheter indicating that 
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hydrogel/silver coatings have the potential to delay the onset of catheter associated infections [33]. 
Synergistic combinations of antibiotic(s) and/or antiseptics are also utilized clinically to reduce the 
incidence of infection. ARROWgard™ central venous catheters are coated by a combination of silver 
sulphadiazine and chlorhexidine, whilst the commercially available alternatives BioGuard Spectrum™ 
and Cook Spectrum® are both coated by a combination of minocycline and rifampicin [34]. Silver 
sulphadiazine and chlorhexidine coated catheters displayed significant activity against a range of 
microorganisms including Candida albicans and Escherichia coli for up to seven days [35]. 
Minocycline-rifampicin catheters were shown to display only bacteriostatic activity against slime 
producing forms of Staphylococcus epidermidis (ATCC 35984) and Staphylococcus aureus (ATCC 
29213) but for an extended period of up to 21 days [36]. A range of other anti-infective biomaterials are 
available commercially, aiming to deliver antimicrobials locally at the device surface for the prevention 
of biofilm formation. Many challenges exist with this strategy. It is difficult to ensure the dose of 
antimicrobial delivered is uniform within the vicinity of the device surface. Areas of the implant may be 
exposed to sub-therapeutic concentrations of antimicrobials [37]. Sub-inhibitory concentrations of 
antimicrobial agents may lead to increased microbial resistance. Research by Rachid highlighted this 
effect whereby an increase in ica operon expression [38], linked with staphylococcal polysaccharide 
intercellular adhesin accumulation [39,40], occurred in response to sub-optimal levels of the antibiotic 
tetracycline and the semi-synthetic molecule quinuprisin- dalfopristin. 
One of the major limitations regarding the delivery of antimicrobials in a biomaterial model is the 
effect of burst-release. Burst-release is consistent with an initial high and rapid release of the 
antimicrobial from the biomaterial. It is one of the major challenges of modern drug delivery. The 
antimicrobial reservoir depletes to sub-inhibitory levels within days allowing infection to develop 
unchallenged. Covalent attachment of antimicrobial, as outlined by the examples of ARROWgard™, 
BioGuard Spectrum™ and Cook Spectrum®, suffer from a reduction in activity due to masking of 
antimicrobials by the host’s conditioning film [41]. A significant profile of prolonged release over weeks 
or an infection responsive system is more desirable [42]. A multitude of studies exist in antimicrobial 
drug delivery to resolve this issue. Examples include sustained release systems such as calcium-mediated 
delivery of the broad-spectrum antibiotic minocycline, as demonstrated by Zhang and colleagues [29]. 
The authors utilized layer-by-layer assembly and calcium binding to create a sustained release platform. 
Delivery of minocycline is due to a local change in pH in the vicinity of the device. Acidosis present in 
the tissues as a result of medical device induced inflammation or infection, weakens the chelation 
reaction between minocycline and calcium ions, resulting in subsequent release of minocycline. This so-
called ‘smart’ approach to drug delivery shows promise for future biomedical application. 
There has also been increasing interest in using peptides for biomaterial applications [43]. As 
antimicrobials, peptides serve as barriers to infection throughout nature as part of the innate immune 
response [44]. There are a multitude of examples whereby antimicrobial peptides have been synthesized 
to disrupt microbial biofilms [45–47]. Peptides also display a diverse array of properties making them 
suitable for biomaterial applications including: increased biocompatibility and minimal 
immunogenicity; the availability of moieties for functionalization; chemical versatility and 
biodegradability [48]. Peptides have also demonstrated an ability to self-assemble into supramolecular 
hydrogels in response to environmental stimuli for example pH, the presence of salts, heat and enzymatic 
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cleavage [49,50]. These characteristics may allow such compounds to be utilized to form inherently 
antimicrobial peptide hydrogel structures in response to infection. 
3. Current Approaches to Self-Assembling Biomaterials 
The process of self-assembly is an important parameter for the development of novel biomaterials. It 
is particularly relevant with regards to nanotechnology. These principles have been adopted from nature. 
Ribosomes and the quaternary haemoglobin structures are examples of naturally occurring  
self-assembled architectures [51]. Assembly involves the spontaneous arrangement of pre-existing, 
disordered molecules of similar properties, to form higher ordered structures. It is mediated by  
non-covalent, local interactions: van der Waals forces, hydrogen bonding, π-π stacking, and electrostatic 
interactions [52,53]. Movement at a molecular level facilitates assembly. Environmental factors such as 
volume and binding influence assembly. Equilibrium between the aggregate and non-aggregate states is 
essential to maintain a higher ordered structure [54,55]. Self-assembly has recently attracted heavy 
investment from both the private and public sectors. In 2010 global public investment was estimated at 
approximately $8.2 billion and private sector funding slightly higher at $9.6 billion [56]. 
Current polymer technologies include the area of Pluronics or poloxamers. Composed of three 
polymers polyoxyethylene (PEO), polyoxypropylene (PPO) and polyoxyethylene (PEO), Pluronics is an 
area that has been extensively studied with regard to micellization and the formation of structures for 
drug delivery purposes. Pluronics have the ability to assemble at physiological temperatures, in a variety 
of solvents, and over a range of concentrations as opposed to a single critical concentration [57]. There is 
a great deal of interest within the drug delivery field in exploiting gels that have the ability to flow at 
ambient temperatures but form a gel upon exposure to physiological temperatures. These gels have great 
potential in terms of targeted or localized drug delivery of anticancer and antimicrobial drugs in 
particular [58]. Self-assembling Pluronics are examples of non-ionic and non-toxic gels [59]. F127 is an 
example of a Pluronic polymer whereby assembly is triggered due to temperature change. Its ability to 
form micelles at human body temperature means that F127 has potential in the delivery of poorly soluble, 
hydrophobic drugs [57]. Sustained release of drugs from Pluronics has been widely investigated. 
Barichello’s group used F127 alone and in addition to poly-co-glycolic acid (PLGA) nanoparticles for 
protein delivery, using insulin as a model drug [60]. They demonstrated F127 incorporated insulin has 
the potential to provide a controlled release system. The short-acting, opioid analgesic fentanyl has also 
been delivered using gels formed by PEO-PPO-PEO. Investigations have shown to demonstrate a similar 
release flux to the commercially available Durogesic® patch [59]. The possibility exists that this type of 
delivery could be adopted for sustained delivery of antimicrobials to wounds or burns, removing the 
need for frequent changes of dressings. The antibiofilm activity of Pluronics has been studied due to its 
non-ionic surfactant-like properties [61]. Wesenberg-Ward and colleagues discovered that Pluronic 
F127 conditioned polystyrene reduced Candida albicans biofilm formation relative to untreated 
polystyrene controls [62]. Reduction in Staphylococcus aureus and Staphylococcus epidermidis 
adherence to polymethylmethacrylate and increased susceptibility to vancomycin and gentamicin was 
also observed in the presence of  poloxamer 407 [63]. These studies highlight the potential use of 
Pluronics in the biomaterials field to produce surfaces that are resistant to microbial adhesion. Recent 
research by Leszczyńska outlined the use of Pluronic F127 topical antimicrobial in combination with 
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the synthetic cationic antibacterial peptide Ceragenin CSA-13 [64]. In this instance, Pluronic F127 acted 
as the drug delivery vehicle with broad spectrum activity demonstrated against methicillin-resistant 
Staphylococcus aureus and a Pseudomonas aeruginosa strain isolated from cystic fibrosis patients. 
Pluronics have also been linked with increased wound-healing in animal models validating continuous 
research into their applications as effective biomaterials [65]. 
Related research combines innovative approaches to stimulate antimicrobial release with self-assembled 
hydrogel polymers. Norris and colleagues synthesized a self-assembled poly(2-hydroxyethyl methacrylate) 
coating containing ordered methylene chains [66]. This polymer released ciprofloxacin in response to 
low intensity ultrasound and displayed significantly reduced accumulation of established 24 h 
Pseudomonas aeruginosa biofilm over a three day period. Self-assembled monolayers have been created 
to modify the surface properties of biomaterials with the aim of reducing bacterial attachment. Recently 
Kruszewski et al. produced stainless steel, commonly employed in orthopaedic implants, modified by a 
self-assembled monolayer of long alkyl chains terminated with hydrophobic (−CH3) or hydrophilic 
(oligoethylene glycol) tail groups [67]. These groups facilitated the attachment of gentamicin or 
vancomycin and reduced Staphylococcus aureus biofilm formation for up to 24 and 48 h respectively. 
Protein deposition by the host conditioning film remains a problem due to masking of covalently 
attached molecules. Studies exist for self-assembled monolayer materials that display resistance to 
biofilm formation and host protein adsorption. Self-assembled monolayers of alkanethiols, presenting a 
tri(ethylene glycol) functional group, displayed a profile of reduced protein adsorption and mammalian 
cell adhesion and resisted Escherichia coli biofilm formation [68]. The authors concluded this may be 
due to the ability of tri(ethylene glycol) to repel cells and inhibit bacterial cell motility, a key factor in 
biofilm formation. Silicon coated with a self-assembled micro-gel consisting of poly(ethylene glycol) 
and poly(ethylene glycol)-co-acrylic acid proved resistant to adhesion by Staphylococcus epidermidis 
for up to 10 h [69]. Loading the micro-gel with an antimicrobial peptide (L5) resulted in significant  
anti-adherent properties at the 10 h time-point due to the localized release and inhibitory action of the 
L5 peptide. After 10 h, colonization was observed due to depletion of the peptide reservoir. 
Such approaches have been significant in advancing biofilm-resistant self-assembled polymer 
research. Limitations exist affecting translation into clinical practice, namely sufficient antimicrobial 
action over a sustained period of time. Self-assembled polymers have contributed to a multitude of 
innovative investigations and applications within biomedical engineering. It is now a widely accepted 
method of material development. The theory has been expanded to investigate the potential of peptide 
self-assembly and peptide-based nanomaterials. Self-assembled peptides display great promise as 
antimicrobial coatings. Alteration of the peptide backbone allows materials to be tailored to their 
application. The production of an inherently antimicrobial peptide hydrogel, which self-assembles in 
response to environmental or specific pathogenic stimuli, may allow for significant reduction of biofilm 
formation over a prolonged period. 
Uses for self-assembled peptides range from medical to engineering applications. They have recently 
come to the fore of bioscience contributing significantly to the nanotech revolution [70]. Work by Zhang 
in 1993 on ionic self-complementary peptides is regarded as particularly noteworthy in terms of evolving 
this area [71]. Other experts of note include: Aggeli, who investigated the hierarchical structures of 
peptides [72]; Tirrell, who patented secondary structure forming peptide amphiphiles [27,73]; and Ghadiri, 
who was responsible for the development of cyclic nanopeptides [74]. To fully understand the potential 
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of self-assembling peptides in biomaterial applications an appreciation of the chemical composition 
governing their hierarchical properties is required. 
Peptides are ideal building blocks for the formation of nanostructures. Utilizing a “bottom up” 
approach, individual amino acid residues are used to build higher ordered structures [75]. The twenty 
naturally occurring amino acids alone allow a huge variety of potential combinations. Their structures 
and corresponding single letter abbreviation are detailed in Figure 1. An immense range of primary 
peptide sequences and higher ordered structures can be created for biomedical applications. Variation of 
the R-group at the alpha (α) carbon provides unique characteristics (hydrophobic, hydrophilic, aliphatic, 
aromatic, positive or negative charge) to each amino acid. These influence the extent to which the 
molecules can participate in non-covalent interactions and therefore self-assemble to form defined 
nanostructures. The hydrophobic: hydrophilic balance and ability of these molecules to hydrogen bond 
are particularly influential factors [55]. Ulijn and Smith provide detail regarding the effect of various 
amino acids on the process of assembly [76]. Their review refers to the relationship between an increase 
in methylene chains on the R-group side chain; the degree of hydrophobicity; and extent of steric 
hindrance in affecting assembly of monomer units. In particular, the degree of hydrophobicity is key in 
determining assembly. Peptide assembly is also influenced by the concentration of peptide present. 
Increasing the number of amino acid repeats results in the formation of higher assemblies. The number 
of amino acids present also affects the critical concentration of assembly. The critical concentration 
increases relative to a rise in the number of amino acid residues due to a shift in the entropic-enthalpic 
balance. For assembly to occur entropic loss must be balanced with an enthalpic gain within the  
system [77]. Environmental factors such as pH, temperature, light, and the presence of proteolytic 
enzymes influence assembly. Peptide systems commonly follow those found in nature. The greater the 
number of hydrophobic residues present, the lower the critical concentration for assembly to occur. 
Crucially the degree of charge and hydrophilicity must be optimal to ensure efficient assembly. An 
increase in hydrophobicity above optimal levels may result in precipitation of the peptide molecule in 
solution. Hydrophilic groups, including those present within the peptide bond (−NHCO), carboxylic 
acids (−COOH) and amines (−NH2) can also contribute to assembly via hydrogen bond intermolecular 
interactions with surrounding solvent and neighboring peptide molecules. Charged amino acids, for 
example lysine, result in charge-charge electrostatic interactions. These have potential to drive or prevent 
assembly depending on the degree of polarity and charge density. Salt concentration is also a 
contributing factor, as demonstrated through work on the peptide EAK16-II by Hong and  
colleagues [78]. A low salt concentration resulted in a desired level of intermolecular interaction, driving 
assembly. Ionisation, which is strongly linked to pH and pKa, has a large influence on the self-assembly 
process. The natural amino acid tyrosine allows further functionalization of peptide molecules. Its R-
group consists of an amphiphilic phenol grouping which allows, for example, formation of imines under 
relatively mild conditions (pH ~6.5) [79]. The use of microbial enzymes to facilitate self-assembly of 
antimicrobial peptides is covered in detail in Section 5.4. The phenol grouping of tyrosine provides an 
alternative functional group for conjugation of possible microbial enzyme targets, for example phosphate 
groupings [80]. 
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Figure 1. The structures and single amino acid code for the twenty naturally occurring amino 
acids. Each amino acid shares a carboxylic acid (−COOH) and a primary amine group 
(−NH2). The properties of the individual amino acids are governed by the nature and 
functionality of the R-group attached to the α-carbon. Researchers exploit the differences in 
individual amino acid units to develop peptide-based therapeutics. Of particular importance 
to antimicrobial peptides and peptide self-assembly is the hydrophobic: hydrophilic balance 
of the primary peptide structure. 
 
Peptide derivatives as detailed include amphiphiles and π-stacked aromatic peptides. Amphiphiles 
have a similar structure to membrane phospholipids, possessing a hydrophobic alkyl tail conjugated to 
a charged moiety. They are ideal molecules for interacting with and disrupting bacterial membranes [81]. 
Assembly results in a variety of higher structures, mainly rods, which possess a hydrophobic core and a 
hydrophilic exterior. The process of assembly is modified by altering the charge of the residues involved 
or by changing the position of the alkyl chain on the alternative termini (amine or carboxylic acid 
functional groups) [82]. Conjugated amphiphilic peptides with assembling properties for example 
IKVAV, have been employed in tissue engineering where the assembled nanofibrous network created 
scaffolds facilitating differentiation of cells into neurons [83]. 
Reviews such as those by Gazit and Martinez [84,85] provide more detailed information regarding π-
stacked peptides. In brief, π-stacked peptides are composed of residues with aromatic groups such as 
phenylalanine, tryptophan, tyrosine and histidine. Burley and Petsko [86] initially investigated the 
aforementioned, naturally occurring aromatic amino acids, and their interactions with neighboring 
aromatic moieties. They highlighted the influence of a residue’s environment on the availability of free 
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energy to interact with other residues, and the contribution of this to the resulting structural stability. 
More recently π-π interactions particularly diphenylalanine interactions, are attracting a great deal of 
interest. They have a key role in β-amyloid polypeptide/ fibril formation and subsequent formation of 
fibrous plaques, which are implicated in disease states such as Alzheimer’s [87]. π-π stacking may also 
be attributed to peptides that have a 9-fluorenylmethoxycarbonyl (Fmoc), naphthalene (Nap), or 
benzyloxycarbonyl (Cbz) group on the amine terminal (Figure 2). π-stacking occurs due to the presence 
of a conjugated system, allowing the aromatic π electrons within this system to overlap and interact [88]. 
The restricted geometries within the aromatic systems provide direction to the assembled structure, with 
interactions between the stacks acting as a glue and contributing to the overall rigidity of such assembled 
structures [84]. 
Figure 2. Examples of aromatic moieties utilized to provide π-π electrostatic interactions. 
The polycyclic aromatic hydrocarbon residues of fluorene (in 9-fluorenylmethoxycarbonyl 
groups), naphthalene (as in 2-naphthylacetyl) and benzene (as in 2-benzyloxycarbonyl) 
facilitates π-stacking due to the presence of a conjugated system of delocalized π-electrons. 
Such intermolecular interactions are enhanced by the presence of hydrophobic aromatic 
amino acid molecules, for example phenylalanine. 
 
Although the aim of assembly is to achieve higher-ordered structures, these must be uniform, 
homogenous and reproducible with defined and useful properties. Peptides provide an ideal basis for 
such structures for many reasons. They are biocompatible and biodegradable [89]. Their synthesis is 
relatively uncomplicated [90]. They can assemble (forming gels) in situ [71]. Peptide bioactivity, such 
as antimicrobial potency, can also be modified according to the amino acid residues selected and 
structure activity relationships can often be determined with high levels of precision. Aromatic groups 
contribute to π-π intermolecular van der Waal’s interactions. Molecules that contain such groups act as 
hydrogelators by supplying increased hydrophobic bulk to the molecule. Fmoc, naphthalene, and Cbz 
may facilitate assembly at a reduced peptide length and cost. Naphthalene is preferred due to an 
established safety profile as it is used in many licensed drug molecules including propranolol. The 
cytotoxicity of naphthalene-based peptides was previously investigated by Yang and co-workers [89]. 
They determined a cell survival of almost 100% when HeLa cells were exposed to 200 micromolar of 
naphthalene dipeptides. Supramolecular properties of these structures including electrical, mechanical 
and bioactivity are also determined by the process and kinetics of self-assembly. Therefore the nature of 
the route and rate of assembly must also be carefully considered when designing self-assembling  
peptide systems. 
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4. Antimicrobial Peptides 
The chemical, physical and structural properties that govern peptide self-assembly are closely 
associated with factors that determine the antimicrobial potency and spectrum of activity of 
antimicrobial peptides. Antimicrobial peptides occur throughout nature and are involved in the innate 
immune response. This response is mounted a short time following exposure to an infective agent and 
stimulation of cells known as Toll-like receptors [91]. Unlike conventional antimicrobials, most 
naturally occurring antimicrobial peptides act synergistically in great numbers and at micromolar 
concentrations. The combined effect of this is a relatively potent antimicrobial response due to action at 
multiple sites, in comparison to a single target as is the case with most conventional antibiotics [92]. 
The amphiphilicity of antimicrobial peptides allows them to target microbial cell membranes, 
particularly those of bacterial cells. Bacterial membranes possess an overall negative charge, compared 
with neutrally charged eukaryotic membranes, due to the presence of acidic hydroxylated phospholipids. 
These include cardiolipin, phosphatidylglycerol and phosphatidylserine [93]. The presence of phosphate 
groups on membrane-bound lipopolysaccharides in Gram-negative bacteria and acidic polymers, such 
as teichoic acids, in Gram-positive bacteria, allow areas of dense anionic charge to develop on bacterial 
membranes [44]. Cationic peptides target these areas to exert their effect. Antimicrobial peptides act 
directly on the cell membrane by disrupting the integrity or function of the phospholipid bilayer via four 
recognized mechanisms: the aggregate, toroidal pore, barrel-stave and carpet models [94]. Bacterial 
membranes are an excellent antimicrobial target as bacteria would be required to alter the overall 
properties of their membrane to confer resistance characteristics, rather than modifying individual 
receptors. The likelihood for bacteria developing resistance is significantly decreased as antimicrobial 
peptides also possess intracellular targets. Peptides have been proven to inhibit ATP-dependent enzymes 
and disrupt processes within the cell, for example RNA and protein synthesis, DNA replication and 
protein folding [95–99]. 
Cationic peptides are the most studied form of antimicrobial peptides. Possessing a net positive 
charge, they are most commonly composed of 12–50 amino acids, approximately 50% of which are 
hydrophobic [100]. Cationic antimicrobial peptides were first derived from insect haemolymph in the 
1970s. They are amphiphilic in nature enabling them to interact with the dense phospholipid exterior of 
bacterial cell membranes [95]. Cationic peptides have been referred to as ‘nature’s antibiotics,’ however 
the term “defence proteins” may be more appropriate due to their role in modulating the innate immune 
response [101]. Anionic peptides are also found throughout nature and have a role in providing innate 
immunity in a variety of animals and plants. Typically, composed of 7–50 residues, they are also 
amphiphilic in nature but have an overall net negative charge due to the presence of aspartic acid  
residues [102,103]. Anionic peptides often require cationic co-factors, for example zinc ions, to produce 
an antimicrobial effect. Brogden hypothesized zinc ions may form a cationic salt bridge between anionic 
antimicrobial peptides and the anionic microbial cell surface [104]. These interactions facilitate 
movement of such peptides across the bacterial membrane, into the cell cytoplasm, allowing intracellular 
attack. Epithelial cells are prime locations for host defense anionic peptides, not only are they key sites 
for ion exchange but they are also commonly exposed to pathogenic microbes [105]. 
Antimicrobial activity and self-assembly of peptides are influenced by similar factors namely: charge, 
bulk and lipophilicity. Strøm and co-workers investigated the contribution of these factors to 
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antimicrobial activity [106]. Their findings showed that an optimal balance exists between degree of 
hydrophobicity or bulk and charge governing antimicrobial potency and spectrum of activity. Modification 
of the peptide sequence with unnatural molecules possessing amino and/or carboxylic acid groups may 
be of benefit in increasing the cost-effectiveness and activity of the peptide. For example, the addition 
of cinnamic acid has been shown to increase antimicrobial activity by providing hydrophobic bulk to the 
primary peptide sequence, at a reduced cost compared with commercially available hydrophobic amino 
acids [107]. Hydrophobicity and antimicrobial activity can be optimized sequentially via the addition of 
fatty acids to the peptide motif, creating the promising antimicrobial lipopeptides [45,108]. The type and 
nature of amino acids employed to generate peptide motifs are also important. Utilizing unnatural amino 
acids, for example ornithine, may provide the peptide with stability against proteases which are unable 
to be recognized at a molecular level for incorporation into enzyme active sites [107]. Most amino acids 
in nature are present as the L-stereoisomer form. Stereoisomerism is based on the ability of molecules to 
rotate plane-polarized light. L-amino acids are easily recognized by host and bacterial enzymes. They 
are ideal substrates for proteolysis by peptide specific enzymes termed proteases. In theory this limitation 
can be reduced, to increase both therapeutic efficacy and retention within the host, by replacement with 
D-amino acids. Amino acids that are in the D-enantiomeric form do not fit in the active site of proteases 
and therefore cannot be broken down. D-amino acids do have limitations. They are typically expensive, 
and for short peptides the realistic enzyme stability they offer is debatable [109]. 
Lipopeptides are a form of antimicrobial peptides present in nature among bacteria and provide 
selective advantage against competing microbial strains. Their success is reflected in the pharmaceutical 
industry, with antimicrobial lipopeptides already successfully utilized clinically. These include anionic 
daptomycin [110], which forms micelles in the presence of calcium ions facilitating membrane 
interaction, and cationic polymyxins which interact with membrane-bound lipopolysaccharides inserting 
into bacterial membranes causing membrane disruption [111]. Cost and toxicity has rendered their use 
restricted to mainly topical application and second or even third line treatments for pathogens resistant 
to other antimicrobials. A research paper by Levine presented the findings of patients registered on the 
Cubicin® Outcomes Registry and Experience (CORE) 2004 database. This covered patients 
administered with the injectable form of daptomycin (brand name: Cubicin®) for the treatment of 
infective endocarditis [112]. Of those treated, 83% of Staphylococcus aureus infections were methicillin 
resistant, and 43% enterococci infections were vancomycin resistant. The findings showed that 
daptomycin has a potential role in treating these types of infections, with 63% of treatments proving 
successful overall. Similarly a review by Li highlights in great detail the effective role of polymyxin E 
(colistin) via inhalation and intravenous administration to treat multi-resistant pseudomonal infections in 
cystic fibrosis patients [113]. There is a clinical need to improve toxicity, bioavailability, and selectivity 
profiles. Activity is influenced by the amino acid chain and hydrophobicity, with the length of the 
conjugated fatty acid chain an influential factor [91]. 
Research is increasingly focused on the action of antimicrobial peptides against resistant biofilm 
phenotypes [114]. Evidence shows that peptides interact with polysaccharide components of the biofilm 
causing break down within the polymeric matrix [115]. Peptides also act synergistically with standardly 
employed antimicrobials, eradicating the biofilm and membrane barriers, allowing clinically employed 
antibiotics access to intracellular targets. The antimicrobial peptides magainin-II (amphibian-derived) 
and cecropin-A (insect-derived) were proven by Cirioni et al. to act synergistically with rifampicin 
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against multi-drug resistant Pseudomonas aeruginosa in both in vivo and in vitro models [116]. The 
lipopeptide polymyxin E demonstrated synergistic efficacy with ticarcillin/clavulanate against 
Stenotrophomonas maltophilia isolated from cystic fibrosis patients [117]. Infectious diseases and their 
causative pathogens continue to display a profile of increased resistance to standardly employed 
antimicrobials. A recent investigation in a Spanish hospital urology department showed that 
approximately 52% of isolated Escherichia coli and 36% Pseudomonas aeruginosa displayed resistance 
to fluoroquinolones [118]. There is a pressing need not only to develop new antimicrobials but also to 
refine the properties of these potentially novel chemotherapeutics so that stability, size, immunogenicity, 
and cost-effectiveness can be improved [119]. The area of antimicrobial peptides hold much promise in 
the development of antimicrobial therapeutics and their potential is covered in more detail in reviews by 
Bahar [47] and our own research group [44]. 
Ultrashort refers to peptides up to 7 amino acids in length. They have become increasingly attractive 
in the development of peptide therapeutics due to reduction in associated cost and ease of synthesis. 
Amino acids are rationally selected in line with a minimum pharmacophore required to permit 
antimicrobial activity [120]. Residues are selected to achieve an optimal lipophilic-charge balance. 
Typically, more active short peptides are the result of greater lipophilic bulk provided by non-proteinogenic 
groups. Strøm and co-workers investigated the effect of ultrashort antimicrobial peptides on a variety of 
nosocomial bacteria including methicillin resistant and sensitive Staphylococcus aureus, methicillin 
resistant Staphylococcus epidermidis and Escherichia coli and defined the minimum motif required for 
activity [106]. They hypothesized that activity in staphylococci required a combination of no more than 
two units of hydrophobic bulk and two units of charge. The Gram-negative rod required three units of 
bulk and at least two charged species for antibacterial activity to be observed. Such specificity allows 
ultrashort antimicrobial peptide therapy to be potentially tailored to causative microorganisms in 
infectious diseases. Harnessing this theory allowed the development of ultrashort lipopeptide variants. 
Peptides composed of four amino acids and a general sequence of KXXK (K = lysine, X = one of leucine, 
alanine, glycine, lysine or glutamic acid) were characterized for activity by the Shai group [108]. Aliphatic 
chains of various lengths were conjugated to these molecules. The resulting ultrashort lipopeptides were 
tested against a variety of bacteria, fungi, and yeast: Escherichia coli, Pseudomonas aeruginosa, 
Staphylococcus aureus, gentamicin-resistant Acinetobacter baumannii, Aspergillus fumigatus, 
Aspergillus flavus, and Candida albicans. This study resulted in three key findings. (1) The aliphatic side 
chain compensated for a reduced peptide chain length and contributed to hydrophobicity of the structure 
and resulting antimicrobial properties; (2) Substrate specificity is linked to the amino acid sequence or 
aliphatic chain length; (3) Many conventional antimicrobial peptides display activity against specific 
microbes. Some of the lipopeptides tested displayed activity against fungi as well as bacteria. Our own 
group used these finding together with the work of Bisht et al. to produce a series of ultrashort cationic 
lipopeptides [107]. Based on an ornithine-ornithine-tryptophan-tryptophan tetrapeptide amide motif, our 
group sequentially increased the lipophilic tail via conjugation of fatty acids to the ornithine terminus. 
C12-ornithine-ornithine-tryptophan-tryptophan displayed the most potent activity particularly against 
Gram-positive bacteria with complete eradication obtained within 24 h exposure against mature biofilms 
of Staphylococcus epidermidis (ATCC 35984) at concentrations as low as 15 µg/mL [45]. The group 
demonstrated it was possible to incorporate the peptide and the amphibian peptide maximin-4 into a 
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poly(2-hydroxyethyl methacrylate) hydrogel in order to prevent short-term (24 h) Staphylococcus 
epidermidis biofilm adherence [46]. 
An alternative approach is to tag the end of the peptide residues with hydrophobic, bulky aromatics 
such as phenylalanine and tryptophan. Work on this area has involved ultrashort peptides composed of 
4–7 amino acid residues. As with lipopeptides, these compounds are amphiphilic in nature and readily 
interact with target cell membranes. Of the tagged peptides investigated by Pasupuleti and  
colleagues [121], the most potent molecule, KNK10-WWWWW, displayed similar antimicrobial 
activity to human cathelicidin LL-37. Findings were similar for the phenylalanine-tagged peptides. 
Tagging also gave increased protection against proteolysis, providing an advantage for such compounds 
over the enzymatically degradable LL-37. This protection may be attributed to steric hindrance resulting 
from the bulky nature of the tags employed, preventing incorporation of the peptide into the protease 
active site. 
Oligo-acyl-lysines (OAKs) are peptidomimetic molecules that mimic the primary structure and 
function of naturally occurring peptides. They are composed of acyl-lysines, with the acyl chain length 
determining hydrophobicity of the molecule and lysine conferring cationic charge for targeting of 
bacterial membranes or inhibition of cellular processes linked to intracellular DNA [122]. They can be 
linked to an inert resin to enhance the ability of OAKs to bind and capture bacteria for pathogen 
detection. A study conducted by Rotem and colleagues demonstrated that resin-bound OAKs have the 
potential to capture both Gram-positive and Gram-negative bacteria under continuous flow and 
stationary settings [123]. These molecules may be useful in terms of filtration of contaminated samples 
including drinking water in a hospital or community setting. Antimicrobial activity of OAKs has also 
been investigated in vivo highlighting their clinical potential. Livne demonstrated OAKs incorporating 
synergistic erythromycin had improved survival rates in neutropenic mice infected with multi-drug 
resistant Escherichia coli compared to erythromycin or OAK monotherapy [124]. Sarig determined the 
optimal lipid mixtures in the preparation of OAK-erythromycin cochleates, utilized for drug delivery [125]. 
Housing OAK molecules in a cochleate drug-delivery vehicle produced molecules with enhanced in vivo 
erythromycin efficacy. Cochleates are a drug delivery vehicle consisting of liposome-like molecules 
formed by a lipid-based supramolecular assembly of natural products (phosphatidylserine), negatively 
charged phospholipid and a divalent cation (calcium). The work of Sarig underlines the importance of 
the drug delivery vehicle in ensuring promising in vitro results for antimicrobial peptide-like molecules 
are translated efficiently to clinical practice. This is the greatest challenge in drug development and is 
particularly difficult with regard to peptides and proteins which suffer from poor solubility, 
pharmacokinetic properties, stability and antigenicity issues [126]. Hence antimicrobial peptides are 
often limited to topical use. The short peptides structures outlined possess many pharmaceutical 
advantages compared with larger peptide/protein molecules as their macromolecular structure allows for 
decreased recognition by proteases and antigens, with potential extension of their pharmacokinetic 
profile [127]. 
5. Self-Assembled Antimicrobial Peptides 
The development of peptides that self-assemble upon exposure to environmental stimuli is of 
increasing interest in biomedicine. The ability to modify a peptide to assemble on cue provides the 
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peptide with a range of desirable properties and potential applications including targeted drug delivery 
in the area of antimicrobials. For biomaterials, preventing the formation of a highly resistant biofilm 
phenotype is pivotal in preventing infection throughout the life of the material [128]. Harnessing 
environmental changes is a significant strategy to deliver activity when most required. Potential triggers 
for the formation of an inherently antimicrobial self-assembling hydrogel include: pH and ionic  
strength [50], temperature [129], light [130] and microbial enzymes [131]. 
5.1. Self-Assembly via Changes in pH and Ionic Strength 
pH and ionic strength are the most commonly utilized methods to achieve assembly and disassembly 
of peptides on cue. Charge interactions are crucial to the assembly process and are influenced by the pKa 
of the peptide, the amino acid backbone and substituent functional groups. The effect of salt on pH-
triggered assembly is also an important factor in determining the degree of ionic interactions [78]. The 
Schneider group is responsible for a large body of research in this area. They developed a synthetic 
peptide MAX-1, which adopted a beta(β)-hairpin structure due to the presence of a central VDPPT 
peptide motif (V = D-enantiomer of valine, DP = D-enantiomer of proline, T = threonine) [132]. Lysine 
and valine amino acid residues flank the type-II β-turn structure in alternating sequences. Basic pH, 
above the pKa of lysine’s primary amine R-group (pH > 9) resulted in self-assembly as intramolecular 
folding resulted in a hydrophobic valine core surrounded by a hydrophilic lysine surface. Lowering the 
pH, below the pKa of lysine favored charge repulsion and disassembly. Addition of buffered saline (150 
millimolar sodium chloride) or Dulbecco’s Modified Eagle’s Medium (165 millimolar sodium chloride) 
to 2% w/v of MAX-1 in water at pH 7.4 directed the formation of a biocompatible hydrogel. Formation 
of a hydrogel was due to screening of positive charged lysine moieties by chloride ions and alteration of 
the hydrophobic: charge balance allowing a decrease in solubility, therefore promoting assembly [133]. 
Replacing lysine with aspartic acid at amino acid position 15 (MAX-8) lowered the overall  
charge of the molecule by +2 and was sufficient to decrease gelation time from 30 min (for MAX-1) to 
1 min [134]. Encapsulation of antimicrobial drugs and/or cells into this matrix could conceivably allow 
the targeted delivery of a hydrogel dressing for wound application via a syringe. This is especially  
true as MAX-1 was proven to display inherent antimicrobial properties against a broad spectrum of 
Gram-positive (Staphylococcus epidermidis, Staphylococcus aureus and Streptococcus pyogenes) and 
Gram-negative (Klebsiella pneumoniae and Escherichia coli) bacteria [132]. The results obtained 
highlight the role of the polycationic lysine surface in compromising negatively charged bacterial 
membranes resulting in bacterial cell death (Figure 3). The Schneider group altered the MAX1 template 
further to produce second generation cationic self-assembled antimicrobial hydrogels containing both 
cationic arginine and lysine residues [132]. MARG1, consisting of two arginine residues, was highly 
potent against methicillin resistant Staphylococcus aureus. A second peptide molecule, PEP6R, 
consisting of six arginines within its peptide primary structure, demonstrated broad spectrum activity 
against Staphylococcus aureus, Escherichia coli and multi-drug resistant Pseudomonas aeruginosa. 
Both were able to form hydrogels at physiological pH. 
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Figure 3. The antibacterial mechanism of action of self-assembling β-sheet cationic peptides 
using the example of MAX1 peptide developed by the Schneider group [132]. Basic pH, 
above the pKa of lysine’s primary amine R-group (pH > 9), results in self-assembly of the 
primary peptide motif into a β-sheet secondary structure. The central VDPPT peptide forms 
a type II β-turn resulting in the formation of a hydrophobic valine core (blue) and a 
hydrophilic cationic lysine face (red). The primary amine (−NH2) R-groups of lysine 
protrude from the β-sheet structure forming a surface of polycationic character that is 
selective for negatively charged bacterial membranes. Adhesion and biofilm formation is 
prevented as bacterial membranes are compromised resulting in leakage of cell contents and 
bacterial cell death. In the hydrogel form the cationic groups may also displace divalent metal 
ions from the bacterial cell wall causing membrane disruption in biofilm cells, leading to cell 
death in both Gram-positive and –negative pathogens. 
 
A related arginine rich peptide PEP8R (containing 8 arginine residues) was also created [135]. 
Variations of PEP8R were prepared, with arginine residues replaced by lysines to determine the optimal 
number of arginines required to achieve an antimicrobial effect. Decreasing the number of arginine 
residues formed PEP6R, a peptide that formed more rigid gels. The variants at all percentages tested 
were active against Escherichia coli and Staphylococcus aureus. Gels containing only two arginine 
residues demonstrated limited activity against Gram-negative Escherichia coli. Peptide derivatives were 
more active against Gram-positive bacteria. The presence of divalent ions such as calcium (Ca2+) reduced 
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the peptides antimicrobial activity. The group concluded that in order to achieve optimal antimicrobial 
activity a minimum of four arginine residues were required. 
Recent research by Liu and colleagues demonstrated the rational design of a pH dependent  
self-assembled antimicrobial peptide (ASCP1) consisting of two peripheral (KIGAKI)3-NH2 species 
conjugated to a central tetrapeptide linker (TDPPG) [50]. Similarly to the MAX peptides, the central 
motif allowed for the formation of a predominantly β-sheet structure with a central β-hairpin at pH 
greater than 10. The presence of twelve lysine primary amine side chains created sufficient electrostatic 
repulsion to prevent self-assembly. Elimination of these net charges via an increase in pH or addition of 
greater than 40 millimolar sodium chloride permits self-assembly. ASCP1 displayed inherent 
antibacterial properties against cultures of Escherichia coli after 36 h incubation. High bacterial loads 
(greater than 107 colony forming units per mL) resulted in loss of inhibitory capacity. Again membrane 
disruption due to the presence of polycationic lysine residues was the most plausible mechanism for 
antibacterial activity. 
RADA16 is one of the most comprehensively studied self-assembled peptides due to its ability to 
self-assemble at physiological pH [136]. Marketed commercially as PuraMatrix™ it has the ability to 
support cell growth and attachment leading to research into its use as a nanofiber scaffold to support 
wound healing. It has been hypothesized that functionalisation with antimicrobials and wound healing 
stimulants, such as epidermal growth factor, provide wound protection while encouraging wound  
closure [137]. Debnath and co-workers developed antimicrobial peptide amphiphiles which self-assemble 
at physiological pH [138]. These Fmoc pyridinium functionalised peptides were tested against a variety of 
Gram-positive (Bacillus subtilis and Staphylococcus aureus) and Gram-negative (Escherichia coli and 
Pseudomonas aeruginosa) bacteria, with minimum inhibitory concentrations determined. Compounds with 
the most broad-spectrum antimicrobial effect had hydrophobic phenylalanine closely attached to the 
Fmoc moiety. The close proximity of fluorenyl and phenyl moieties allowed an optimum 
hydrophobicity, described by the authors as the “threshold hydrophobicity”, to be obtained thus allowing 
significant activity against bacteria via membrane attack. 
pH triggered self-assembly has potential to be utilized in antimicrobial therapies. Urinary catheter 
associated infections are synonymous with an increase in alkaline conditions due to the presence of the 
enzyme urease synthesized by Gram-negative Proteus mirabilis. Urease catalyses the breakdown of urea 
to ammonia via hydrolysis leading to increased pH at the urine-catheter interface and the precipitation 
of mineral salts such as calcium phosphate (hydroxyapatite) and magnesium ammonium phosphate 
(struvite). A combination of encrustation and biofilm formation leads to blockage of the catheter, with 
removal of the device necessary to resolve infection [139]. We hypothesize a role whereby an 
antimicrobial peptide may self-assemble at the device surface in response to an increase in pH (or the 
presence of urease) forming a protective barrier, reducing biofilm formation and encrustation thus 
preventing the need for catheter removal. This strategy would require the peptide molecule to be attached 
to the catheter surface, physicochemically stable at pH 7.4 and active against a broad spectrum of urinary 
pathogens, especially biofilm forms of Proteus mirabilis. 
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5.2. Photo-Activated Self-Assembly 
Light may be used as an environmental trigger for the formation of hydrogels. These are typically 
formed when a water-soluble polymer and photo-initiator are exposed to a specific wavelength of light 
and crosslinking occurs. The resulting hydrogels display temporal and spatial resolution. Macromolecules 
are the preferred starting material and these are chosen to achieve the desired crosslinking and 
mechanical properties for the final hydrogel. The photo-initiator must be sufficiently reactive yet 
cytocompatible. Exposure to ultraviolet light triggers arrangement of a peptide into β-hairpins and 
subsequent self-assembly to a hydrogel occurs provided that the side chains permit this. Cysteine is 
hydrophobic in nature and easily functionalized. Therefore it is a useful side chain component for 
facilitating assembly. An example of this type of assembly is the 20-residue MAX7CNB peptide [130]. 
This caged (α- carboxy-2 nitrobenzyl) peptide is unfolded in ambient conditions but exposure to UV 
light triggers decaging and peptide folding to form a supramolecular hydrogel. There is no specific 
investigation in the literature for a peptide that induces self-assembly and antimicrobial activity in 
response to light. The use of light to stimulate antimicrobial delivery has been evaluated previously and 
therefore may serve as a valid mechanism for future research. McCoy and colleagues, developed an 
antimicrobial biomaterial containing tetracationic porphyrin, (tetrakis(4-N-methylpyridyl)porphyrin), 
which binds electrostatically with methacrylate groups of a methacrylic acid or a methyl methacrylate 
copolymer [140]. Visible light allowed the porphyrin to catalytically generate short-lived singlet oxygen 
at the device surface, with antimicrobial activity displayed against Staphylococcus aureus and 
Pseudomonas aeruginosa. 
5.3. Thermo-Responsive Self-Assembly 
Temperature can be used as a trigger to form higher assemblies (hydrogel structures) either through 
cooling or heating of molecules. The degree of hydrophobicity governs the temperature at which folding 
occurs. Typically, assembly of more hydrophobic molecules takes place at a lower temperature [141]. 
Schneider and colleagues modified their MAX-1 peptide, which forms a hydrogel at 25 °C and pH 9, by 
the replacement of two valine residues (at amino acid positions 7 and 16) with threonine [141]. This 
resulted in a peptide that formed hydrogel structures at higher temperatures (~60 °C). A replacement at 
position 16 only resulted in a gelation temperature of 40 °C, only slightly above that of normal body 
temperature, suggesting possible use as a thermo-responsive hydrogel in drug delivery. Liu’s ASCP1 
peptide displayed similar self-supporting hydrogel structures at higher temperatures (~60 °C) [50]. 
Temperature change alters the solubility of the hydrophobic amino acid residues in these peptides,  
thus altering the hydrophobic: hydrophilic balance to favor decreased solubility. The process is 
thermally-reversible. Temperature-responsive gelation is not only limited to large peptide structures. 
Tang discovered replacing the terminal phenylalanine residue in Fmoc–FF with glycine (forming 
FmocFG) created a peptide that also gelled at increased temperatures [142]. Rheological analysis below 
its pKa demonstrated self-assembly had occurred at 25 °C but only sufficient to produce a viscous 
solution. Gelation occurred between 55 and 80 °C which the authors attributed to dissolution of 
precipitate, formed due to a low pH, allowing homogenous hydrogels to be formed in solution. Further 
work by Tang studied glycine and leucine substituted Fmoc dipeptides [143]. In addition, employing pH 
Pathogens 2014, 3 809 
 
 
and temperature to facilitate the formation of Fmoc hydrogels, FmocFG and FmocLG gelation proved 
also to be temperature-dependent. Both FmocFG and FmocLG hydrogels formed upon heating to 80 °C. 
Mechanical properties were retained upon subsequent cooling of heated peptides to 25 °C and 4 °C. 
FmocLG appeared to gel at 25 °C, with further heating and cooling of this gel to 4 °C forming stiffer 
hydrogel structures. This confirmed that a heating step was shown to improve the homogeneity of the 
samples without altering the topography of the self-assembled structures. Therefore, hydrophobicity of 
the peptide molecule, pH and homogeneity in aqueous solutions have to be taken into account in the 
design of a temperature triggered antimicrobial self-assembly peptide structure. 
5.4. Bacterial Enzymatic Self-Assembly 
Enzyme mediated self-assembly occurs as a result of catalysis or removal of a blocking group within the 
peptide primary sequence. It occurs under standard physiological conditions (pH and temperature) [144]. 
Enzymes such as proteases [145], phosphatases [49] and esterases [146], serve as viable molecules to 
drive peptide self-assembly. Catalysis occurs due to a thermodynamic shift resulting from condensation 
or hydrolysis of the peptide bond. In some cases both of these processes may occur in order to form 
peptide structures that are more stable. Research by Toledano demonstrated environmentally dependent 
protease triggered reverse hydrolysis of Fmoc amino acids [147]. Enzymes are selected, and the 
concentrations modified, in order to achieve optimum assembly under a defined set of conditions [148]. 
Enzymatic approaches to self-assembly are becoming more popular in research due to the abundance of 
bacterial enzymes, allowing tailored specificity for selected pathogens. 
As outlined previously (Section 3), selection of specific amino acid residues and their corresponding 
properties is crucial in developing ultrashort peptides. Investigations into self-assembling ultrashort 
antimicrobial peptides are relatively novel but are increasing in the literature, especially in the area of 
enzyme triggered self-assembly. Removal or addition of one or two amino acid units has a larger 
influence on the overall properties of short peptide structures, including its solubility and therefore ability 
to self-assemble. One of the first examples of such research was conducted by the Xu group [49]. They 
were able to demonstrate that a strain of Escherichia coli, that overexpressed a phosphatase enzyme, was 
able to be selectively inhibited by a short naphthalene containing peptide. Dephosphorylation of soluble 
phosphorylated NapFFY(p), NapDFDFY(p) and Nap-β3-HPhg-β3-HPhgY(p) (β3-HPhg: a β-amino acid 
named β3-homophenylglycine, p: phosphorylated) occurred in the cell cytoplasm causing inhibition of 
multiple intracellular processes resulting in a reduction in bacterial viability. Further work by the Xu 
group demonstrated how peptide self-assembly can be governed by a tyrosine-linked kinase/phosphatase 
switch [80]. Phosphorylation (via kinase) and dephosphorylation (via phosphatase) of the hydrogelator 
at the tyrosine terminus regulated the formation of supramolecular hydrogels. Gelation occurred in vivo 
in the presence of phosphatase enzyme, as removal of hydrophilic phosphate groupings increased the 
hydrophobicity of the molecule, driving self-assembly. The presence of phosphatases have been 
attributed to medical device related pathogens such as Escherichia coli, where alkaline phosphatase is 
present in the periplasmic space and therefore serves as a valid microbial target [149,150]. The Xu  
group [151] also produced a NapFF precursor conjugated to a β-lactam ring, capable of hydrogelation 
in response to the addition of β-lactamase enzymes from cell lysates of Escherichia coli. This mechanism 
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has potential to be exploited for the detection of extended spectrum β-lactamases in a clinical setting and 
allowing screening of potential inhibitors.  
Enzymatic assembly of ultrashort peptides, utilizing alkaline phosphatase, has been conducted more 
recently by the Ulijn group [131]. The Fmoc dipeptides (FY, YT, YS, YN and YQ in a FmocYpX-OH 
motif, where X = any amino acid) were central to the study, with tyrosine providing the hydroxyl 
grouping for phosphorylation. Phosphorous nuclear magnetic resonance (31P NMR) allowed 
determination of the rate of dephosphorylation and inhibition within defined areas of the bacterial cell 
and enabled the location of formed fibers to be identified. Treatment with alkaline phosphatase facilitates 
protonation of phosphate groups and the formation of higher assemblies. Peptide hydrogels formed over 
24 h. Assembly was evident at a molecular level and there was evidence of β sheets, hydrogen bonding 
and π-stacking. Ability to assemble in vivo was investigated using media with and without the nucleoside 
inosine, which increases alkaline phosphatase synthesis two-fold. Bacterial cells were treated with a 
FmocFYp-OH precursor and HPLC analysis showed that the peptide moved into the hydrophobic 
environment of the bacterial cells. This demonstrated that assembly could occur in vivo. Treatment of 
Escherichia coli cells with other precursors showed similar results (self-assembly) however the effect of 
hydrophobicity on assembly and the resulting location of the formed peptides varied. More hydrophilic 
peptides were more likely to partition into the surrounding media rather than remaining within the 
hydrophobic environment of the bacterial cell. The findings indicated that formation of the peptides 
followed by movement out of the bacterial cells was sufficient to significantly reduce the number of viable 
bacterial cells. Therefore retention of the formed nanostructure within the cells was not essential to exert 
an antimicrobial effect. The intracellular and extracellular modes of action of these peptides reduce the 
ability of bacteria to develop resistance and bode well for their future development as therapeutics. The 
Ulijn group also employed the esterase subtilisin, obtained from the soil derived bacterium Bacillus 
licheniformis, as a mediator for assembly of Fmoc dipeptide methyl esters proving the versatility of the 
enzymatic approach to allow self-assembly [146]. 
6. Future Perspectives and Translation of Peptide Self-Assembly to Antimicrobial Therapeutics 
Challenges exist to the use of peptides as antimicrobial therapeutics. There is currently only one 
licensed self-assembled peptide therapeutic; the injectable β-sheet forming octapeptide lanreotide 
administered for the relief of neuroendocrine symptoms [152]. The licensing of lanreotide by the Food 
and Drug administration in 2007 provides great hope that similar molecules can be translated into 
therapeutics. In antimicrobial drug delivery there is increasing research into the utilization of  
self-assembled peptides as practical therapeutics. It is becoming increasingly relevant in the innovative 
production of antimicrobials and their delivery platforms. Peptide self-assembly has been utilized in 
combination with standardly employed antibiotics. Marchesan et al., produced a macroscopic  
tripeptide hydrogel (DLFF) at physiological pH which incorporated the sparingly soluble antibiotic 
ciprofloxacin [153]. The hydrophobic tripeptide acted as a suitable drug delivery vehicle for the release 
of ciprofloxacin in vitro. Mild antibiofilm activity was demonstrated for the tripeptide alone against 
Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae, with significant reduction in 
viability obtained via inclusion of 30% w/w ciprofloxacin. 
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Paladini and co-workers investigated the antimicrobial effects of silver incorporated into ultrashort 
Fmoc diphenylalanine (FmocFF) hydrogels on Staphylococcus aureus. [154]. Hydrogels (as detailed in 
Section 2) are commonly used in wound management and can be impregnated with antimicrobial agents, 
including silver. The nature of the hydrogels themselves creates a hydrated environment and protects the 
wound, creating an ideal environment for wound healing. Self-assembling peptide hydrogels such as 
those formed from assembly of FmocFF create a similar environment, making them ideal candidates for 
wound dressings. Paladini’s ‘silver-doped’ FmocFF hydrogels are composed of varying concentrations 
of silver nitrate (0.01%, 0.1%, 2% weight). The hydrogels produced were used to coat flax textiles and 
exposed to Staphylococcus aureus overnight. The work demonstrated the ability of FmocFF to 
disassemble and reassemble when added to the flax substrates. Scanning electron microscopy suggested 
that the higher the concentration of silver present, the more uniform the nature of the flax coverage. 
Precipitates formed with the 2% w/v gels thus homogeneity was not achieved. Antimicrobial studies 
demonstrated a reduction in bacterial numbers with an increased silver concentration. Bacterial adhesion 
and biofilm formation was also investigated. Incorporation of silver was necessary to prevent biofilm 
formation and the minimum concentration of silver needed to achieve this effect was 0.1% weight. 
The amphipathic peptide, FmocFFECG, contains both hydrophobic and hydrophilic moieties. The 
presence of carboxylic acid functionalities allowed adsorption of silver nanoparticles into the peptide 
motif [155]. Activity was proven against Gram-positive Bacillus subtilis and Gram-negative Escherichia 
coli for up to 30 days. Stability was also increased compared with silver nanoparticles alone suggesting 
the peptide hydrogel protects silver nanoparticles from oxidation. The hydrophobic character of 
ultrashort self-assembling peptides may also allow the incorporation of other highly lipophilic 
antimicrobial drugs. 
Peptides also provide access to infections in the brain. Research by Liu demonstrated how the peptide 
CG3R6TAT (C = hydrophobic cholesterol, G = glycine spacers, R = cationic arginine residues,  
TAT = minimal amino acid sequence required for membrane translocation) assembles to form micelles 
with a hydrophobic cholesterol core and hydrophilic peptide exterior [156]. This peptide displays 
antimicrobial activity against a range of Gram-positive and Gram–negative bacteria. Ability to cross the 
blood brain barrier and exert an antimicrobial effect was also demonstrated in vivo in an infected 
Staphylococcus aureus induced meningitis rabbit model. This work highlights the ability of assembled 
peptides as tailored molecules to achieve targeted antimicrobial effects in challenging areas of  
drug delivery. 
Key problems associated with peptide design namely, high manufacturing costs and susceptibility to 
enzymatic degradation, mean there is still a need to develop compounds that have similar properties to 
conventional antimicrobial peptides in physiological conditions namely: cationic charge, hydrophobicity and 
amphiphilic nature to enable antimicrobial action and self-assembly. Peptidomimetics and other 
synthetic oligomers are thus coming to the forefront of current and future research plans. The design of 
ultrashort peptides has the potential to create functional peptide molecules with a relatively reasonable 
manufacturing cost. Our own group has moved research forward in this area with the synthesis of a 
variety of ultrashort and more cost-effective cationic naphthalene containing peptide hydrogels, which 
are highly active against biofilm forms of biomaterial related pathogens [157]. The very nature of 
peptides and their proven activity against pathogenic biofilms renders them useful compounds for 
prevention and management of nosocomial infections and wound healing. Further development of 
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peptidomimetics will provide novel biomaterial platforms and the development of new molecules with 
tunable chemical and mechanical properties. 
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